Clinical trial

Single-Dose Islatravir in Moderate Hepatic Impairment (MK-8591-030)

NCT04515641

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2020-11-05

PhasePHASE1

Study timeline

Study start (actual)2020-11-05Date precision: day

Registry last updated2025-07-17

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Human Immunodeficiency Virus (HIV) Infectionunresolved

Interventions

IslatravirDRUG · verified · RxNorm: islatravir

Sponsors & collaborators

Merck Sharp & Dohme LLClead sponsor

Mapped research locations

MiamiFlorida, United States1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT04515641 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.